Overview

Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer

Status:
Active, not recruiting

Trial end date:
2024-09-30

Target enrollment:

Participant gender:

Summary

Determine the doses and schedule appropriate for phase 2 study of sorafenib and vorinostat with concurrent gemcitabine and radiation therapy (RT) as neoadjuvant treatment of pancreatic cancer following chemotherapy. Recommended phase II dose RP2Ds and schedule of sorafenib and vorinostat defined as the doses and schedule that are the same as or less than the maximum tolerated dose (MTD) and schedule.

Phase:

Phase 1

Details

Lead Sponsor:

Virginia Commonwealth University

Collaborator:

National Cancer Institute (NCI)

Treatments:

Gemcitabine
Niacinamide
Sorafenib
Vorinostat